{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:14:41Z","timestamp":1789388081211,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,2]],"date-time":"2027-03-02T00:00:00Z","timestamp":1803945600000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["T32AI083216"],"award-info":[{"award-number":["T32AI083216"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.anai.2025.11.008","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:49:16Z","timestamp":1763657356000},"page":"249-256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Emerging IgE and non-IgE targeted therapies for chronic urticaria"],"prefix":"10.1016","volume":"136","author":[{"given":"Krishan D.","family":"Chhiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-2742","authenticated-orcid":false,"given":"Sarbjit S.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.anai.2025.11.008_bib0001","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2025.11.008_bib0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","article-title":"Urticaria","volume":"8","author":"Kolkhir","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.anai.2025.11.008_bib0003","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaad.2019.02.064","article-title":"Prevalence estimates for chronic urticaria in the United States: A sex- and age-adjusted population analysis","volume":"81","author":"Wertenteil","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2025.11.008_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2024.1487831","article-title":"Key differences between chronic inducible and spontaneous urticaria","volume":"5","author":"Bizjak","year":"2024","journal-title":"Front Allergy"},{"issue":"2","key":"10.1016\/j.anai.2025.11.008_bib0005","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaip.2023.11.029","article-title":"Comorbid inducible urticaria is linked to non-autoimmune chronic spontaneous urticaria: CURE insights","volume":"12","author":"Kovalkova","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.anai.2025.11.008_bib0006","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.jaip.2023.08.020","article-title":"Patients with chronic spontaneous urticaria who have wheals, angioedema, or both, differ demographically, clinically, and in response to treatment-results from CURE","volume":"11","author":"Buttgereit","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2025.11.008_bib0007","first-page":"12","article-title":"Prevalence of concomitant angioedema in chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"41","author":"Weerasubpong","year":"2023","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.11.008_bib0008","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.jaip.2021.03.038","article-title":"A comparative study of sex distribution, autoimmunity, blood, and inflammatory parameters in chronic spontaneous urticaria with angioedema and chronic histaminergic angioedema","volume":"9","author":"Sabat\u00e9-Bresc\u00f3","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2025.11.008_bib0009","series-title":"Global Urticaria Forum","article-title":"A survey on prognosis of acute urticaria of 1075 patients in ten clinics in Hiroshima [abstract]","author":"Kamigaki","year":"2024"},{"issue":"5","key":"10.1016\/j.anai.2025.11.008_bib0010","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaip.2016.11.037","article-title":"Chronic idiopathic urticaria: systemic complaints and their relationship with disease and immune measures","volume":"5","author":"Doong","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2025.11.008_bib0011","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA\u00b2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2025.11.008_bib0012","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13601-017-0141-3","article-title":"Effectiveness and safety of antihistamines up to 4-fold or higher in treatment of chronic spontaneous urticaria","volume":"7","author":"van den Elzen","year":"2017","journal-title":"Clin Transl Allergy"},{"issue":"6","key":"10.1016\/j.anai.2025.11.008_bib0013","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"175","author":"Guill\u00e9n-Aguinaga","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.008_bib0014","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40360-023-00665-y","article-title":"The efficacy and safety of high-dose nonsedating antihistamines in chronic spontaneous urticaria: a systematic review and meta-analysis of randomized clinical trials","volume":"24","author":"Xiao","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.anai.2025.11.008_bib0015","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jaci.2024.05.026","article-title":"Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: systematic review and meta-analysis of randomized clinical trials","volume":"154","author":"Rayner","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2025.11.008_bib0016","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jaip.2019.10.018","article-title":"High-dose omalizumab use in patients with chronic spontaneous urticaria","volume":"8","author":"Alizadeh Aghdam","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2025.11.008_bib0017","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaip.2015.04.015","article-title":"Similar efficacy with omalizumab in chronic idiopathic\/spontaneous urticaria despite different background therapy","volume":"3","author":"Casale","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"suppl 5","key":"10.1016\/j.anai.2025.11.008_bib0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jdv.13697","article-title":"Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria","volume":"30","author":"Gim\u00e9nez-Arnau","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.anai.2025.11.008_bib0019","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2025.11.008_bib0020","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2025.11.008_bib0021","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaip.2019.08.025","article-title":"Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment","volume":"8","author":"Kolkhir","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2025.11.008_bib0022","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2500\/aap.2011.32.3483","article-title":"Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria","volume":"32","author":"Magen","year":"2011","journal-title":"Allergy Asthma Proc"},{"issue":"12","key":"10.1016\/j.anai.2025.11.008_bib0023","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/all.13586","article-title":"Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab","volume":"73","author":"Weller","year":"2018","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.anai.2025.11.008_bib0024","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jaip.2017.10.030","article-title":"Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria","volume":"6","author":"Straesser","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2025.11.008_bib0025","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaip.2015.11.025","article-title":"Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria","volume":"4","author":"Palacios","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2025.11.008_bib0026","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.11.008_bib0027","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2025.11.008_bib0028","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2340\/00015555-2654","article-title":"Basophil Fc\u03b5RI expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy","volume":"97","author":"Deza","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.anai.2025.11.008_bib0029","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.jaci.2021.02.038","article-title":"The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes","volume":"147","author":"Johal","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.11.008_bib0030","doi-asserted-by":"crossref","first-page":"AB208","DOI":"10.1016\/j.jaci.2024.12.645","article-title":"Biopredictors for omalizumab response in patients with chronic spontaneous urticaria (CSU) [abstract]","volume":"155","author":"Le","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.11.008_bib0031","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaci.2025.06.004","article-title":"Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: systematic review and network meta-analysis","volume":"156","author":"Chu","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2025.11.008_bib0032","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"10422","key":"10.1016\/j.anai.2025.11.008_bib0033","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","article-title":"Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials","volume":"403","author":"Maurer","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.anai.2025.11.008_bib0034","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1111\/all.16446","article-title":"CT-P39 compared with reference omalizumab in chronic spontaneous urticaria: results from a double-blind, randomized, active-controlled, Phase 3 study","volume":"80","author":"Saini","year":"2025","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2025.11.008_bib0035","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70264","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity profiles of a single-dose JYB1904 in healthy Chinese participants: a phase Ia, randomized, double-blind, placebo-controlled study","volume":"18","author":"Shen","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.anai.2025.11.008_bib0036","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.70074","article-title":"LP-003, a novel high-affinity anti-IgE antibody for inadequately controlled seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled phase 2 clinical trial","volume":"15","author":"Guan","year":"2025","journal-title":"Clin Transl Allergy"},{"issue":"15","key":"10.1016\/j.anai.2025.11.008_bib0037","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157765","article-title":"IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms","volume":"132","author":"Kuo","year":"2022","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.anai.2025.11.008_bib0038","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/jid.2014.512","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.anai.2025.11.008_bib0039","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1172\/JCI138448","article-title":"Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1016\/j.anai.2025.11.008_bib0040","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172335","article-title":"A phase II study of bruton's tyrosine kinase inhibition for the prevention of anaphylaxis","volume":"133","author":"Suresh","year":"2023","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.anai.2025.11.008_bib0041","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaci.2025.05.030","article-title":"Current and future landscape of Bruton tyrosine kinase inhibitors in allergy","volume":"156","author":"Lin","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2025.11.008_bib0042","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton's tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.anai.2025.11.008_bib0043","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2025.11.008_bib0044","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2023.10.007","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks","volume":"153","author":"Jain","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.11.008_bib0045","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.anai.2024.08.317","article-title":"No clinically meaningful impact of remibrutinib on immunoglobulin levels or infections in chronic spontaneous urticaria","volume":"133","author":"Palumbo","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2025.11.008_bib0046","series-title":"ACTRIMS Congress","article-title":"Effect of remibrutinib treatment on the immune response to vaccinations in healthy participants [poster]","author":"Tillmann","year":"2025"},{"issue":"7","key":"10.1016\/j.anai.2025.11.008_bib0047","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/jamadermatol.2025.0733","article-title":"Rilzabrutinib in antihistamine-refractory chronic spontaneous urticaria: the RILECSU Phase 2 randomized clinical trial","volume":"161","author":"Gimenez-Arnau","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.anai.2025.11.008_bib0048","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","article-title":"Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial","volume":"27","author":"Metz","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.anai.2025.11.008_bib0049","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1111\/bcp.14923","article-title":"Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: results of a phase 1a\/b randomised double-blind placebo-controlled study","volume":"87","author":"Dickson","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.008_bib0050","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (Liberty-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.11.008_bib0051","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.anai.2024.10.005","article-title":"Dupilumab significantly improves itch and hives in patients with chronic spontaneous urticaria (CUPID study C)","volume":"133","author":"Casale","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.anai.2025.11.008_bib0052","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.jaip.2025.06.014","article-title":"Exploring mepolizumab use in chronic spontaneous urticaria: an open-label, single-arm, exploratory study","volume":"13","author":"Phillipps","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2025.11.008_bib0053","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/bjd\/ljae067","article-title":"Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial","volume":"191","author":"Altrichter","year":"2024","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.anai.2025.11.008_bib0054","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1111\/all.16190","article-title":"Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation","volume":"79","author":"Gil-Martinez","year":"2024","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2025.11.008_bib0055","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jaci.2025.01.045","article-title":"Tezepelumab for the treatment of chronic spontaneous urticaria: results of the phase 2b INCEPTION study","volume":"155","author":"McLaren","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.11.008_bib0056","doi-asserted-by":"crossref","first-page":"AB366","DOI":"10.1016\/j.jaci.2023.11.873","article-title":"Barzolvolimab significantly decreases chronic spontaneous urticaria disease activity and is well tolerated: top line results from a Phase 2 trial","volume":"153","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2025.11.008_bib0057","unstructured":"Maurer M., Metz M., Kobielusz-Gembala I., Mitha E., Leflein J., Gotua M., et al. Barzolvolimab shows profound efficacy and favorable safety over 52 weeks in patients with chronic spontaneous urticaria [abstract]. European Academy of Dermatology and Venereology (EADV) Congress. 2024."},{"key":"10.1016\/j.anai.2025.11.008_bib0058","unstructured":"Metz M., Maurer M., Gim\u00e9nez-Arnau A.M. Anderson J., Mitha E., Leflein J., et al. Sustained disease control following withdrawal of barzolvolimab in patients with chronic spontaneous urticaria [abstract]. Glasgow, Scotland. EAACI Annual Meeting. 2025"},{"issue":"8","key":"10.1016\/j.anai.2025.11.008_bib0059","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/all.16598","article-title":"Anti-KIT barzolvolimab for chronic spontaneous urticaria","volume":"80","author":"Maurer","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2025.11.008_bib0060","unstructured":"Celldex. therapeutics announces positive topline results from barzolvolimab Phase 2 study in chronic spontaneous urticaria [press release]. Celldex Therapeutics Investor Relations. 2023. Hampton, NJ. Accessed September 19, 2025; https:\/\/ir.celldex.com\/news-releases\/news-release-details\/celldex-therapeutics-announces-positive-topline-results."},{"issue":"2","key":"10.1016\/j.anai.2025.11.008_bib0061","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1242\/dev.113.2.689","article-title":"Role of c-kit in mouse spermatogenesis: identification of spermatogonia as a specific site of c-kit expression and function","volume":"113","author":"Yoshinaga","year":"1991","journal-title":"Development"},{"issue":"5","key":"10.1016\/j.anai.2025.11.008_bib0062","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/all.15585","article-title":"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria","volume":"78","author":"Terhorst-Molawi","year":"2023","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2025.11.008_bib0063","doi-asserted-by":"crossref","first-page":"AB62","DOI":"10.1016\/j.jaci.2023.11.215","article-title":"BLU-808, a potent and selective small molecule inhibitor of wild-type c-KIT for mast cell disorders","volume":"153","author":"Grassian","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2025.11.008_bib0064","unstructured":"Jasper Therapeutics Reports Positive Data From Beacon Study of Briquilimab in Chronic Spontaneous Urticaria [press release]. 2025. Redwood City, CA. Accessed August 1, 2025; https:\/\/ir.jaspertherapeutics.com\/news-releases\/news-release-details\/jasper-therapeutics-reports-positive-data-beacon-study."},{"key":"10.1016\/j.anai.2025.11.008_bib0065","unstructured":"Jasper therapeutics reports clinical data update from Briquilimab studies in chronic spontaneous urticaria [press release]. Jasper Therapeutics Investor Relations. 2025. Redwood City, CA. Accessed August 7, 2025; https:\/\/ir.jaspertx.com\/news-releases\/news-release-details\/jasper-therapeutics-report-clinical-data-update-briquilimab."},{"issue":"2","key":"10.1016\/j.anai.2025.11.008_bib0066","doi-asserted-by":"crossref","first-page":"AB372","DOI":"10.1016\/j.jaci.2023.11.891","article-title":"Efficacy and Safety of TLL-018 in Moderate to Severe Chronic Spontaneous urticaria Patients with Inadequate Response to H1 antihistamine: results from a Phase \u2160b Study","volume":"153","author":"Lu","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2025.11.008_bib0067","series-title":"ACAAI Annual Meeting","article-title":"Povorcitinib demonstrates rapid improvement in hives and itch in patients with chronic spontaneous urticaria (CSU) [abstract]","author":"Soong","year":"2025"},{"key":"10.1016\/j.anai.2025.11.008_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101799","article-title":"Siglecs as potential targets of therapy in human mast cell- and\/or eosinophil-associated diseases","volume":"69","author":"O\u2019Sullivan","year":"2023","journal-title":"Semin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2025.11.008_bib0069","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625013456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625013456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:35:32Z","timestamp":1773934532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625013456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1081120625013456"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.11.008","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging IgE and non-IgE targeted therapies for chronic urticaria","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}